Background: Thyroid function tests are frequently assessed during pregnancy to evaluate thyroid dysfunction or to monitor pre-existing thyroid disease. However, using non-pregnant reference intervals can lead to misclassification. International guidelines recommended that institutions should calculate their own pregnancyspecific reference intervals for free thyroxine (FT4), free triiodothyronine (FT3) and thyroid-stimulating hormone (TSH). The objective of this study is to establish gestationspecific reference intervals (GRIs) for thyroid function tests in pregnant Turkish women and to compare these with the age-matched non-pregnant women. Methods: Serum samples were collected from 220 nonpregnant women (age: 18-48), and 2460 pregnant women (age: 18-45) with 945 (39%) in the first trimester, 1120 (45%) in the second trimester, and 395 (16%) in the third trimester. TSH, FT4 and FT3 were measured using the Abbott Architect i2000SR analyzer. Results: GRIs of TSH, FT4 and FT3 for first trimester pregnancies were 0.49-2.33 mIU/L, 10.30-18.11 pmol/L and 3.80-5.81 pmol/L, respectively. GRIs for second trimester pregnancies were 0. .90 pmol/L. GRIs for third trimester pregnancies were 0.58-4.31 mIU/L, 10.30-17.89 pmol/L and 3.67-5.81 pmol/L. GRIs for TSH, FT4 and FT3 were different from non-pregnant normal reference intervals. Conclusions: TSH levels showed an increasing trend from the first trimester to the third trimester, whereas both FT4
Introduction
Pregnancy is a prolonged physiological adaptation period resulting in major alterations in maternal thyroid hormone physiology. During pregnancy profound changes in thyroid physiology occur, to meet the increased metabolic needs of the fetus and mother, resulting in different thyroid-stimulating hormone (TSH), free thyroxine (FT4) and free triiodothyronine (FT3) reference intervals compared to the non-pregnant state [1] .
Due to the structural homology between the alpha subunits of human chorionic gonadotropin (hCG) and TSH, hCG binds to the TSH receptor of thyroid follicular cells and stimulates the gland. The thyrotropic action of hCG induces FT4 and FT3 secretion and causes suppression of TSH transiently through a feedback mechanism. In the first trimester, there is a significant negative correlation between the TSH and hCG levels; TSH returns slowly to normal levels after term [1] [2] [3] .
Maternal thyroid dysfunction can have untoward impact on the progress of pregnancy and fetal development. The prevalence of overt hypothyroidism was 1%-1.5%, and prevalence of subclinical hypothyroidism was 5%-8%. Overt hypothyroidism in pregnancy has been shown to be associated with an increased risk of adverse pregnancy outcomes such as miscarriage, fetal death, preterm birth, low birth weight as well as fetal distress in labor, fetal death, congenital hypothyroidism and neurocognitive deficits in children [4] [5] [6] [7] . Subclinical hypothyroidism might be associated with gestational hypertension (eclampsia, preeclampsia), preterm delivery and low Apgar score [7, 8] . Prevalence of hyperthyroidism in pregnant women was 1.5% (overt, 1.2% and subclinical, 0.3%). Maternal hyperthyroidism is associated with increased risk of preeclampsia, preterm delivery, intrauterine growth restriction and neonatal thyrotoxicosis [9] .
Although there is a well-known controversy among scientific societies, screening for thyroid dysfunction during pregnacy is recommended especially in high risk groups including previous thyroid dysfunction, goiter, positive for thyroid antibodies, family history of thyroid disease, cervical irradiation, thyroid surgery, age > 30 years, presence of clinical symptoms of hypothyroidism, diagnosis of any autoimmune disease (e.g. type 1 diabetes mellitus), history of repeated abortions, prematurity, infertility, morbid obesity, treatment with lithium, amiodarone, recent administration of iodinated contrast, or living in an area with iodine deficiency. Some scientific societies have proposed to assess thyroid function before the 10th week of gestation to enable the fetal brain to develop optimal conditions [10] .
Thyroid peroxidase antibodies (TPOAb) and thyroglobulin antibodies (TGAb) are frequently measured to investigate thyroid dysfunction in pregnancy. The presence of TPOAb and/or TGAb has been associated with the possible development of hypothyroidism during gestation and post-partum thyroid dysfunction [11, 12] . It has been shown that thyroid autoantibody positivity decreased between 12 and 25 weeks of gestation, and remained lowered until birth due to maternal immune tolerance with progression of pregnancy. Hence, thyroid autoantibody testing should be performed within the first trimester, rather than second and third trimesters [13] .
Thyroid function of healthy pregnant women differs from that of healthy non-pregnant women. International guidelines recommend that institutions should calculate their own pregnancy-specific reference intervals for FT4, FT3 and TSH instead of using fixed universal cut-off concentrations for non-pregnant women [14, 15] . The aim of this study was to establish gestation specific reference intervals (GRIs) for TSH, FT4 and FT3 for pregnant women in Turkey using the Abbott Architect analyzer and compare them with other GRI studies using the same analyzer. We also aimed to analyze thyroid function tests according to the age group.
Materials and methods

Study population
This retrospective study included 2460 singleton healthy pregnant women (age 18-45, mean 30.5±4.2 years), who were in consecutive antenatal follow-up at Medicana Hospital, Department of Obstetric and Gynecology, Ankara, Turkey between 2013 and 2015. Non-pregnant women (n = 220) aged between 18 and 48 (mean 33.4±6.2 years) who were tested at the routine checkup center of Hacettepe University Hospitals were grouped in age-matched controls. All of the participants filled out a questionnaire requesting information concerning health status, a family history of thyroid diseases, smoking habits, diet, physical exercise and use of medications. The ethnic composition of the pregnant group was similar to that of the non-pregnant controls; basically Turkish ethnic group is a composition of Middle East, Balkans, Eastern Europe and Caucasian.
TSH, FT4, FT3 levels were measured in pregnant women at trimester 1, 2 and 3. Trimester 1 was defined as weeks 4-12, trimester 2 was defined as weeks 13-24 and trimester 3 was defined as > 25 weeks. Pregnancy was confirmed with a positive β-hCG test in the first trimester following a missed period. Sonographic diagnosis of intrauterine pregnacy was also approved by the gestational sac with yolk sac visible.
To rule out the autoimmune thyroid diseases, TgAb and TPOAb were measured in all pregnant women once at their first visit to the gynecologist. The age-matched control group was also screened for TgAb and TPOAb. The women positive for TgAb, and/or TPOAb were excluded from the study. Moreover, women with known chronic thyroid diseases, using thyroid hormone or anti-thyroid medications, chronic hypertension, systemic diseases such as diabetes mellitus Type I or Type II were excluded from the study.
The study design and protocol were approved by the Hacettepe University Ethical Committee.
Thyroid function tests and antibody measurements
For thyroid function tests (TFT), a 10 mL blood sample was collected in serum separator tubes with yellow top (Becton, Dickinson and Company, Franklin Lakes, NJ, USA) at their visit in the first, second and third trimester. Venipuncture was performed after an overnight fast, between 8 and 11 a.m. in the morning. Following centrifugation at 4000 g for 10 min (Rotanto 460R, Hettich, Germany), serum samples were seperated and analyzed immediately. TSH, FT4 and FT3 levels were measured by Architect i2000 SR analyzer (Abbott Diagnostics, Abbott Park, IL, USA) using two-step chemiluminescent microparticle immunoassay (CMIA) technology. The chemiluminescent reaction was measured as relative light units (RLUs) with a direct relationship that exists between the amount of TSH in the sample and the RLUs, in contrast an inverse relationship exists between the RLUs and the amount of FT4 or FT3 in the sample. The assay manufacturer's reference intervals were 0.35-4.94 mU/L for TSH, 9-19 pmol/L for FT4, and 2.62-5.70 pmol/L for FT3 as calculated from individuals with normal thyroid function.
The IgG class of TgAb and TPOAb was determined quantitatively by CMIA using the Architect i2000 SR analyzer. A direct relationship exists between the amount of autoantibodies in the sample and the RLUs detected. The cut-off values for TgAb and TPOAb were 4.11 IU/mL and 5.61 IU/mL.
Statistical analysis
The statistical analysis was performed by using IBM SPSS software, version 21 (SPSS Inc., Chicago, IL, USA) and MedCalc version 14.8.1 (Mariakerke, Belgium). Statistical significance was assumed when the p-value was < 0.05. All results were expressed as mean±standard reached to non-pregnant levels. The median TSH levels showed an increasing trend from the first trimester to the third trimester. There was a significant difference in TSH levels between trimesters 1 and 2, trimester 2 and 3 (p < 0.001).
Trimester specific reference values (mean, median, 2.5th-97.5th percentiles) for FT4 are shown in Table 3 . FT4 levels were significanly lower in trimesters 2 and 3 than for the age matched non-pregnant controls (p = 0.031 and p = 0.021, respectively) but there was no significant difference in FT4 levels between three trimesters as seen in Figure 2 .
Trimester specific reference values (mean, median, 2.5th-97.5th percentiles) for FT3 are shown in Table 4 . FT3 values were significantly higher than those for nonpregnant age matched controls (p < 0.001) in each trimester but no significant rise or fall in FT3 values was observed between trimesters (p = 0.596) (Figure 3 ).
This study has also shown that the pregnancy incidence in Turkey is 10.1% under age 25, 41.9% between ages 26 and 30, 36.3% between ages 31 and 35, and decreases to 11.7% after age 36. Additionally, when the TSH, FT3 and FT4 levels were evaluated according to age groups, no significant difference was observed between ages (p > 0.05).
deviation (SD) and median (minimum-maximum). The MannWhitney U-test was used for the comparision of TSH, FT4 and FT3 values in non-pregnant controls and pregnant women. The KruskalWallis test was used to analyze the significance of differences in TSH, FT4 and FT3 between the groups; the post-hoc Mann-Whitney U-test was used to detect significant changes. Outliers were tested with the D'Agostino-Pearson test. The reference intervals were calculated with a non-parametric percentile method.
Results
TSH, FT4 and FT3 levels were measured in 220 healthy non-pregnant women and 2460 pregnant women with 945 (39%) in the first trimester, 1120 (45%) in the second trimester, and 395 (16%) in the third trimester. TSH, FT4 and FT3 in non-pregnant controls and pregnant women were compared in the Table 1 . FT4 and FT3 levels in pregnant women were significantly different from non-pregnant age matched controls (p = 0.009 and p < 0.001, respectively).
Trimester specific reference values (mean, median, 2.5th-97.5th percentiles) for TSH are shown in Table 2 . The upper reference limits of TSH were below the nonpregnant levels throughout pregnancy. TSH value was significantly lower in trimester 1 than in the non-pregnant age-matched control group (p < 0.001). No significant difference was observed in trimester 2 between pregnant and non-pregnant groups (p = 0.962). TSH was significantly higher in trimester 3 compared to non-pregnant controls (p < 0.001).
As shown in Figure 1 , TSH values were suppressed in the first trimester, rose following the second trimester and 
Discussion
Thyroid function tests are frequently assessed during pregnancy to evaluate thyroid dysfunction or to monitor pre-existing thyroid disease. Using non-pregnant reference intervals can lead to misclassification of normal pregnant women. Therefore, establishing gestation-specific reference intervals in each population is essential for accurate assessment of thyroid function. For this purpose, we have investigated TSH, FT4 and FT3 levels in 2460 healthy singleton pregnant women and 220 non-pregnant women in Turkey. There was a significant increase in TSH levels between trimester 1 and 2, and 2 and 3 (p < 0.001).
The mean±SD values in the first (1.31±0.51) and second Serum TSH level is accepted as an accurate indicator of thyroid status in pregnancy. As a single hormone determination, TSH provides the most sensitive index to reliably detect thyroid dysfunction [16] . We have observed that serum TSH level decreased transiently during the first trimester related to hCG levels, and rose in the second and third trimester in our study similar to those of earlier reports [17] . If trimester-specific reference intervals for TSH are not available in the laboratory, the American Thyroid Association (ATA) recommends the following reference intervals; 0.1-2.5 mIU/L for first trimester, 0.2-3.0 mIU/L for second trimester, 0.3-3.0 mIU/L for third trimester and 4.0 mIU/L for non-pregnant healthy women [18] . In the present study, we established Turkish reference intervals using the Architect i2000 SR analyzer (Abbott Diagnostics). The Turkish reference interval for TSH levels for second trimester (0.51-3.44 mIU/L) and third trimester (0.58-4.31 mIU/L) are higher than the ATA intervals. Besides, the normal interval of TSH for the first trimester (0.49-2.33 mIU/L) is narrow compared to ATA reference intervals. Medici et al. [19] have reviewed a wide range of reference interval studies and reported that 90% of upper limits of TSH were higher than the recommended TSH cut-off values varying between 2.15 and 4.68 mU/L.
During pregnancy, serum TSH levels should be interpreted carefully with FT4 levels because of the variable effects of gestation. When maternal TSH is elevated, measurement of serum FT4 concentration is necessary to pregnant women are complicated by increased thyroid binding globulin (TBG) and decreased albumin concentrations that can cause immunoassays to be unreliable. High TBG concentrations cause higher FT4 values, whereas low albumin yield lower FT4 values. Therefore, the analytical method used for serum FT4 analysis should be taken into consideration [26] . Equilibrium dialysis isotope dilutionliquid chromatography-tandem mass spectrometry (ED IDLC/tandem MS) is an IFCC-approved international conventional reference measurement procedure (cRMP) for free thyroxine [27] . Anckaert et al. [28] have compared three commercial immunassays (Cobas 600-Roche, Immulite 2000-Siemens and Architect i2000SR-Abbott) with ED IDLC/tandem MS. Their study confirmed that the all three immunassays were sensitive to pregnancy-specific protein alterations, to different extents, and gave a similar pattern to ED IDLC-tandem MS for FT4 measurements. Although ED IDLC/tandem MS is recommended for FT4 analysis with higher specificity in comparison to immunoassays, it is not used widely for measurement of free thyroid hormones due to high instrumental costs.
The IFCC Committee for Standardization of Thyroid Function Tests (C-STFT) conducted a phase III method comparison study involving eight manufacturers of FT4 and TSH assays. They have shown that all FT4 assays were negatively biased in the mid-to high-concentration interval, with an interassay discrepancy of approximately 30%. However, the maximum deviation was approximately 90% in the low range. They concluded that standardization/harmonization would be of great benefit for both FT4 and TSH, especially in the low concentration range [29] .
Bestwick et al. [30] suggest that if TSH and FT4 values can be expressed as multiple of medians (MoM), the cutoff points of different assays can be standardized more easily. MoM value can be calculated by dividing each individual's value by the population median, and is independent of interassay differences.
Not only the differences in laboratory methods but also maternal iodine status, ethnic, genetic, and environmental factors could explain the differences in values seen in several studies [31] . We compared our results with selected GRI studies especially for TSH, FT4 and FT3 by Architect i2000SR (Abbott) as shown in Table 5 .
Dhatt et al. [23] evaluated a mixed ethnic population of pregnant women in the United Arab Emirates. There was a significant difference in TSH levels between trimesters 1 and 2, and 2 and 3 (p < 0.005) but no significant difference between the ethnic groups. Mean FT4 and FT3 levels decreased significantly with each progressive trimester in all groups [22, 23, 32] , especially between the first and second trimesters (p < 0.005). In contrast, we did classify either subclinical or overt hypothyroidism [20] . According to the guideline of ATA in 2011, overt hypothyroidism is defined as an elevated TSH ( > 2.5 mIU/L) in conjunction with a decreased FT4 concentration. Women with TSH levels of 10.0 mIU/L or above, irrespective of their FT4 levels, are considered to have overt hypothyroidism. Subclinical hypothyroidism is defined as a serum TSH between 2.5 and 10 mIU/L with a normal FT4 concentration. On the contrary, overt hyperthyroidism was defined as suppressed TSH ( < 0.2 mIU/L) accompanied by high FT4 or with TSH < 0.1 mIU/L irrespective of FT4 level. Subclinical hyperthyroidism was defined as suppressed TSH (0.1-0.2 mIU/L) with normal FT4 [18] .
In several studies, both FT4 and FT3 has been reported to increase by up to 50% during the first trimester and decline with progression of gestation (during the second and third trimester) to 20%-40% below the normal level [17, 21, 22] . In our study, FT4 reference values were similar to other ethnic groups in the first trimester, but did not show a decline with progression of gestation as reported; rather they remained within the same interval during second and third trimesters [17, [21] [22] [23] . In non-pregnant, age-matched controls, FT4 was significanly higher than pregnant women (p = 0.009). Turkish FT3 levels were uniform throughout gestation, did not show a decrease but were significantly higher than non-pregnant women (p < 0.001). Similar to our results, Mannisto et al. [24] did not observe a clear rise or fall in FT3 values during pregnancy in the Northern Finland prospective cohort study, levels ranging between 3.4 and 7.2 pmol/L.
The differences in FT4 reference values may be related to analytical methods [25] . Serum FT4 measurements in not observed any significant decrease either in FT4 or FT3 levels in our study. Both lower and upper reference values of FT4 in Turkish women were higher than the other studies especially in the second and third trimesters [22, 23, 32] . Stricker et al. [32] described a higher reference limit for TSH at 4-6 weeks (0.44-3.23 mIU/L) compared to 6-12 weeks (0.06-2.82 mIU/L). Indeed, the fall in TSH during the first trimester of pregnancy is very important, women in early pregnancy (4-6 weeks) should not be judged by reference intervals derived from women predominantly in the late first trimester. Gilbert et al. [33] established the lowest reference limits for TSH (0.02-2.15 mIU/L) in the 9-13-week period of pregnant Australian women by the Abbott Architect system. In conclusion, we established gestational reference intervals for TSH, FT4 and FT3 in Turkish pregnant women. This is the first study providing gestation specific reference intervals in Turkey. TSH, FT4 and FT3 levels of Turkish pregnant women may differ from the other studies depending upon geographical, dietary, environmental factors or analytical method related differences. We believe that our trimester and method-specific reference intervals will be useful for the diagnosis and appropriate management of thyroid dysfunction during pregnancy which will prevent both maternal and fetal complications. However, our pregnant group and non-pregnant control group comprises a hospital-based population, which is the limitation of our study. Ideally, reference intervals should be determined using blood samples obtained from a large cohort of healthy subjects.
Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.
